

## Monoclonal Antibody to CD80 - FITC

<b>Alternate names:</b>	Activation B7-1 antigen, B7-1, B7.1, BB1, CD28LG, CD28LG1, CTLA-4 counter-receptor B7.1, LAB7, T-lymphocyte activation antigen CD80
<b>Catalog No.:</b>	SM1742F
<b>Quantity:</b>	100 Tests
<b>Background:</b>	CD80 (B7-1) and CD86 (B7-2) are ligands of T cell critical costimulatory molecule CD28 and of an inhibitory receptor CTLA-4 (CD152). The both B7 molecules are expressed on professional antigen-presenting cells and are essential for T cell activation, the both molecules can also substitute for each other in this process. The question what are the differences in CD80 and CD86 competency has not been fully elucidated yet; there are still conflicts in results about their respective roles in initiation or sustaining of the T cell immune response.
<b>Uniprot ID:</b>	<a href="#">P33681</a>
<b>NCBI:</b>	<a href="#">NP_005182.1</a>
<b>GeneID:</b>	<a href="#">941</a>
<b>Host / Isotype:</b>	Mouse / IgG1
<b>Clone:</b>	MEM-233
<b>Immunogen:</b>	CD80 fusion protein
<b>Format:</b>	<b>State:</b> Liquid purified Ig fraction <b>Buffer System:</b> PBS containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free BSA as a stabilizer <b>Label:</b> FITC – Fluorescein isothiocyanate The reagent is free of unconjugated and adjusted for direct use
<b>Applications:</b>	Flow cytometry analysis of human blood cells using 20 µl reagent / 100 µl of whole blood or 10e6 cells in a suspension. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
<b>Specificity:</b>	The antibody reacts with CD80. <b>Species:</b> Human. Other species not tested.
<b>Storage:</b>	Store the antibody undiluted at 2-8°C. DO NOT FREEZE! This product is photosensitive and should be protected from light. Shelf life: one year from despatch.
<b>Product Citation:</b>	1. Jewon Ryu, Cheol-Whan Lee, Kyung-Hee Hong, Jin-Ae Shin, Sun-Hee Lim, Chan-Sik Park, Jiyeon Shim, Ki Byung Nam, Kee-Joon Choi, You-Ho Kim, and Ki Hoon Han Activation of

**For research and in vitro use only. Not for diagnostic or therapeutic work.**

Material Safety Datasheets are available at [www.acris-antibodies.com](http://www.acris-antibodies.com) or on request.

Antibody Hotline - Technical Questions - Antibody Location Service  
Free Call: 0800-2274746 (Germany only) - [www.acris-antibodies.com](http://www.acris-antibodies.com)

fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia *Cardiovasc Res*, May 2008; 78: 333 - 340.

- General References:**
1. Vasilevko V, Ghochikyan A, Holterman MJ, Agadjanyan MG: CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA. *DNA Cell Biol.* 2002 Mar;21(3):137-49.
  2. Yadav D, Judkowski V, Flodstrom-Tullberg M, Sterling L, Redmond WL, Sherman L, Sarvetnick N. B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets. *J Immunol.* 2004 Sep 15;173(6):3631-9.
  3. Thomas IJ, Petrich de Marquesini LG, Ravanan R, Smith RM, Guerder S, Flavell RA, Wraith DC, Wen L, Wong FS. CD86 has sustained costimulatory effects on CD8 T cells. *J Immunol.* 2007 Nov 1;179(9):5936-46.
  4. Eri R, Kodumudi KN, Summerlin DJ, Srinivasan M. Suppression of colon inflammation by CD80 blockade: Evaluation in two murine models of inflammatory bowel disease. *Inflamm Bowel Dis.* 2008 Jan 9
  5. Campioni D, Moretti S, Ferrari L, Punturieri M, Castoldi GL, Lanza F.: Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. *Haematologica.* 2006 Mar;91(3):364-8.
  6. Zhan H, Towler HM, Calder VL: The immunomodulatory role of human conjunctival epithelial cells. *Invest Ophthalmol Vis Sci.* 2003 Sep;44(9):3906-10.
  7. Kolar GR, Mehta D, Pelayo R, Capra JD: A novel human B cell subpopulation representing the initial germinal center population to express AID. *Blood.* 2007 Mar 15;109(6):2545-52.
  8. Lee DJ, Sieling PA, Ochoa MT, Krutzik SR, Guo B, Hernandez M, Rea TH, Cheng G, Colonna M, Modlin RL: LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. *J Immunol.* 2007 Dec 15;179(12):8128-36.
  9. Silk KM, Leishman AJ, Nishimoto KP, Reddy A, Fairchild PJ: Rapamycin Conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype. *J. Biomed. Biotechnol.*, vol. 2012, article ID 172420, 11 pages, doi:10.1155/2012/172420.

---

**For research and in vitro use only. Not for diagnostic or therapeutic work.**

Material Safety Datasheets are available at [www.acris-antibodies.com](http://www.acris-antibodies.com) or on request.

Antibody Hotline - Technical Questions - Antibody Location Service  
Free Call: 0800-2274746 (Germany only) - [www.acris-antibodies.com](http://www.acris-antibodies.com)